The New York City Collaborative Regional Coordinating Stroke Center

纽约市协作区域中风协调中心

• 批准号: 8896090
• 负责人: LAURA BALCER
• 金额: $ 25.75万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8896090
• 关键词: Academic Medical Centers; Acute; Address; Adult; Agreement; Ambulatory Care Facilities; Area; Awareness; Blood Vessels; Caring; Cessation of life; Childhood; Clinical; Clinical Trials; Cohort Studies; Collaborations; Communities; Development; Enrollment; Epidemiologic Studies; Epidemiology; Epigenetic Process; Ethnic Origin; Evaluation; Future; Gender; Health; Health Professional; Health system; Hispanics; Hospitals; Institutes; Institution; Institutional Review Boards; Israel; Laboratories; Latino; Lead; Leadership; Link; Low income; Medical center; Medicine; Methodology; Minority; Modeling; Morbidity - disease rate; Multi-Institutional Clinical Trial; Municipal Hospitals; Myocardial Infarction; National Institute of Neurological Disorders and Stroke; Neurologist; Neurology; Neurosciences; New York; New York City; Outcome; Patients; Pediatrics; Phase; Population; Prevention; Primary Prevention; Principal Investigator; Protocols documentation; Race; Readiness; Recovery; Recruitment Activity; Rehabilitation Centers; Rehabilitation therapy; Research; Research Infrastructure; Research Personnel; Resources; Risk; Risk Factors; Site; Stroke; Stroke prevention; Structure; System; Teaching Hospitals; Training and Education; Translations; Underrepresented Minority; Universities; Ursidae Family; Woman; acute stroke; base; cohort; college; design; disability; experience; follower of religion Jewish; improved; innovation; medical schools; meetings; mortality; multidisciplinary; next generation; north shore long island; novel strategies; phase II trial; phase III trial; programs; response; screening; success

DESCRIPTION (provided by applicant): Stroke remains a leading cause of mortality, morbidity and disability with gradients in all three outcomes by race-ethnicity and gender. Lower SES groups, including Blacks and Hispanics, suffer a disproportionately high burden of risk, disability and death from stroke, myocardial infarction and associated vascular risk factors. Until recently there has been a dearth of Phase 2 and 3 clinical trials for stroke, and those that have been undertaken have mostly focused only on acute stroke treatment. Additionally, many of these trials were unable to meet trial enrollment targets and had poor recruitment of underrepresented minorities and women. As new stroke treatment approaches emerge, both from neuroscience laboratories and from epidemiologic cohort studies, rapid translation requires the efficient design and implementation of clinical trials in this area. We are responding to RFA-NS-13-011: NINDS Stroke Trials Network-Regional Coordinating Stroke Centers (RCC) with the overall aim to establish a collaborative network that brings together three major urban academic medical centers and their affiliates. The Centers bring with them three large CTSA's and an extensive network system to leverage clinical expertise and research infrastructure to provide multidisciplinary support to maximize the efficient development, promotion, and conduct of high quality multi- site clinical trials, with a focus on stroke prevention, treatment and rehabilitation/recovery in both adult and pediatric populations. The centers include the Albert Einstein College of Medicine (AECOM), Icahn School of Medicine at Mount Sinai (ISMMS), and New York University School of Medicine (NYU). Additionally, Hofstra-North Shore-Long Island Jewish Medical School and Health System together with their network institutions and affiliates. New York City Health and Hospitals Corporation (HHC) facilities; Continuum Health Partners facilities (Beth Israel Medical Center, St. Luke's/Roosevelt Hospital Center); and Maimonides Medical Center join NYCC-RCC as affiliate institutions. Three rehabilitation hospitals, including the preeminent Rusk Institute at NYU, Beth Abraham at Einstein and the Rehabilitation Center at ISMMS are also key network partners.

描述(由申请人提供)：中风仍然是死亡率、发病率和残疾的主要原因，在所有三种结果中都存在种族-民族和性别的梯度。社会经济地位较低的群体，包括黑人和西班牙裔，承受着不成比例的高风险和残疾负担 以及死于中风、心肌梗死和相关的血管危险因素。直到最近，中风的2期和3期临床试验一直很少，而那些已经进行的临床试验大多只专注于急性中风的治疗。此外，这些试验中有许多无法达到试验招募目标，而且对代表性不足的少数群体和妇女的招募也很差。随着新的中风治疗方法的出现，无论是神经科学实验室还是流行病学队列研究，快速转换需要有效的设计 并在这一领域实施临床试验。我们正在响应RFA-NS-13-011：NINDS卒中试验网络-区域协调卒中中心(RCC)，总体目标是建立一个合作网络，将三个主要的城市学术医疗中心及其附属机构聚集在一起。该中心带来了三个大型的CTSA和广泛的网络系统，以利用临床专业知识和研究基础设施提供多学科支持，以最大限度地有效开发、推广和进行高质量的多地点临床试验，重点关注成人和儿童人群的中风预防、治疗和康复/康复。这些中心包括阿尔伯特·爱因斯坦医学院(AECOM)、西奈山伊坎医学院(ISMMS)和纽约大学医学院(NYU)。此外，霍夫斯特拉-北岸-长岛犹太医学院和卫生系统及其网络机构和附属机构。纽约市卫生和医院公司(HHC)的设施、Continuum Health Partners设施(贝丝以色列医疗中心、圣卢克/罗斯福医院中心)和迈蒙尼德医疗中心作为附属机构加入NYCC-RCC。纽约大学著名的拉斯克研究所、爱因斯坦大学的贝丝·亚伯拉罕和ISMMS的康复中心等三家康复医院也是关键的网络合作伙伴。